Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10083913 | 0.87 | — | — | |
| SCHEMBL19351854 | 0.87 | EPHX1 (0.58) | LMNAALDH1A1TSHRFAAHMEN1 | |
| SCHEMBL9856907 | 0.87 | GAA (0.39) | GAALMNAALDH1A1TSHRFAAH | |
| SCHEMBL12245072 | 0.83 | — | — | |
| SCHEMBL11463947 | 0.83 | EPHX1 (0.37) | GAALMNAALDH1A1TSHRFAAH | |
| SCHEMBL6047100 | 0.83 | EPHX1 (0.68) | ALDH1A1FAAHEPHX1MAPTHPGD | |
| SCHEMBL11470826 | 0.83 | EPHX1 (0.37) | GAALMNAALDH1A1TSHRFAAH | |
| SCHEMBL15547605 | 0.81 | EPHX1 (0.50) | ALDH1A1FAAHEPHX1PRMT1SMN1; SMN2 | |
| SCHEMBL16927525 | 0.81 | FAAH (0.37) | GAALMNAALDH1A1TSHRFAAH | |
| SCHEMBL11150877 | 0.81 | SIGMAR1 (0.40) | GAALMNAALDH1A1TSHRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218061-B2 | CARMUSTINE PHARMACEUTICAL COMPOSITION | NAVINTA III INC (US) | 2025-07-02 | — | — | EP | claimed |
| EP-3218061-B1 | CARMUSTINE PHARMACEUTICAL COMPOSITION | NAVINTA III INC (US) | 2022-06-29 | — | — | EP | claimed |
| US-10342769-B2 | Carmustine pharmaceutical composition | NAVINTA III INC (US) | 2019-07-09 | — | — | US | claimed |
| US-20190169116-A1 | PROCESS FOR PREPARATION OF CARMUSTINE | INTAS PHARMACEUTICALS LTD. (IN) | 2019-06-06 | — | — | US | claimed |
| EP-3442941-A1 | PROCESS FOR PREPARATION OF CARMUSTINE | Intas Pharmaceuticals Limited (IN) | 2019-02-20 | — | — | EP | claimed |
| WO-2017178910-A1 | PROCESS FOR PREPARATION OF CARMUSTINE | INTAS PHARMACEUTICALS LTD. (IN) | 2017-10-19 | — | — | WO | claimed |
| WO-2017154019-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-09-14 | — | — | WO | claimed |
| US-20160136116-A1 | Carmustine Pharmaceutical Composition | PROVIDENT BANK | 2016-05-19 | — | — | US | claimed |
| US-4028410-A | Process of preparing 1,3-bis(2-chloroethyl)-1-nitrosourea | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1977-06-07 | — | — | US | claimed |
| US-20250339390-A1 | KIT FOR PREPARING INJECTABLE CARMUSTINE SOLUTIONS | VIVUS LLC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3883865-B2 | SEAL OF A PORTION CAPSULE | GCS GERMAN CAPSULE SOLUTION GMBH (DE) | 2025-11-05 | — | — | EP | disclosed |
| EP-3464530-B1 | CANDLE COMPRISING A COMPOSTABLE PLASTIC ELEMENT | CUP CANDLE GMBH (DE) | 2025-08-27 | — | — | EP | disclosed |
| EP-3218061-B2 | CARMUSTINE PHARMACEUTICAL COMPOSITION | NAVINTA III INC (US) | 2025-07-02 | — | — | EP | disclosed |
| US-11865206-B2 | Stable ready-to-use carmustine pharmaceutical composition | EMCURE PHARMACEUTICALS LTD (IN) | 2024-01-09 | — | — | US | disclosed |
| EP-0841912-A1 | ANTITUMOR 2-AMINOCARBONYL-1,2-BIS(METHYLSULFONYL)-1-(SUBSTITUTED)HYDRAZINES | YALE UNIVERSITY (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5637619-A | Antitumor 2-aminocarbonyl-1, 2-bis(methylsulfonyl)-1-(substituted)hydrazines | YALE UNIVERSITY (US) | 1997-06-10 | — | — | US | disclosed |
| WO-1997002029-A1 | ANTITUMOR 2-AMINOCARBONYL-1,2-BIS(METHYLSULFONYL)-1-(SUBSTITUTED)HYDRAZINES | YALE UNIVERSITY (US) | 1997-01-23 | — | — | WO | disclosed |
| US-4128538-A | Crosslinking polymeric dye mordant composition reaction product of bisalkane or bisarene sulfonate and vinyl polymer | EASTMAN KODAK COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4028410-A | Process of preparing 1,3-bis(2-chloroethyl)-1-nitrosourea | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1977-06-07 | — | — | US | disclosed |
| US-4028410-A | Process of preparing 1,3-bis(2-chloroethyl)-1-nitrosourea | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136116-A1 | Carmustine Pharmaceutical Composition | MGMT, PAICS, CNR2 | GAA 2189/4885LMNA 4408/4885ALDH1A1 951/4885 |
| US-20190169116-A1 | PROCESS FOR PREPARATION OF CARMUSTINE | MGMT, UMPS, HNMT | GAA 1650/4885LMNA 3511/4885ALDH1A1 1479/4885 |
| US-10342769-B2 | Carmustine pharmaceutical composition | MGMT, PAICS, CNR2 | GAA 2189/4885LMNA 4408/4885ALDH1A1 951/4885 |
| US-20250339390-A1 | KIT FOR PREPARING INJECTABLE CARMUSTINE SOLUTIONS | KIT, BRAF, MEN1 | GAA 2424/4885LMNA 3417/4885ALDH1A1 943/4885 |
| US-11865206-B2 | Stable ready-to-use carmustine pharmaceutical composition | SLC5A7, MEN1, PAICS | GAA 2101/4885LMNA 4155/4885ALDH1A1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.